Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Februar 2017 08:30 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9

NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
14. Februar 2017 07:00 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer

NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
08. Februar 2017 08:30 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences

NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other technologies for targeting and treating...
22. Dezember 2016 16:15 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other technologies for targeting and treating...
07. Dezember 2016 08:30 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™

NEW YORK, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
08. November 2016 08:00 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals to Present at Upcoming Investor Conferences

NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
07. November 2016 07:55 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update

Received $50 Million Milestone Payment from Valeant Related to U.S. Approval of RELISTOR® TabletsCommercial Launch of RELISTOR® Tablets in September 2016On November 4th, Monetized Portion of...
07. November 2016 07:45 ET | Quelle: Progenics Pharmaceuticals

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
24. Oktober 2016 08:30 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7

NEW YORK, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
21. Oktober 2016 08:30 ET | Quelle: Progenics Pharmaceuticals

Progenics Pharmaceuticals to Present at the 23rd Annual Prostate Cancer Foundation Scientific Retreat

NEW YORK, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...

Vorherige Seite

Nächste Seite